Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2019 April;60(2) > The Journal of Cardiovascular Surgery 2019 April;60(2):237-44

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE  VASCULAR SECTION 

The Journal of Cardiovascular Surgery 2019 April;60(2):237-44

DOI: 10.23736/S0021-9509.16.09049-2

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

The endovascular treatment of juxta-renal abdominal aortic aneurysm using fenestrated endograft: early and mid-term results

Enrico GALLITTO , Mauro GARGIULO, Antonio FREYRIE, Chiara MASCOLI, Claudio MASSONI BIANCHINI, Stefano ANCETTI, Gianluca FAGGIOLI, Andrea STELLA

Division of Vascular Surgery, University of Bologna, S. Orsola-Malpighi Polyclinic Hospital, Bologna, Italy


PDF


BACKGROUND: The aim of the present study was to evaluate the early and mid-term results of the endovascular treatment of juxta-renal abdominal aortic aneurysms (j-AAA) using fenestrated endograft (FEVAR).
METHODS: Between 2008 to 2013 all consecutive patients underwent FEVAR using Cook-Zenith fenestrated endograft for treating j-AAA (proximal neck length <5 mm) with renal aortic α/β angle <60°, were prospectively collected in a database. Cardiovascular risk factors, comorbidities, aortic-iliac morphological features, intra and post-procedural data were analyzed. Preoperative FEVAR planning was performed by a thoraco-abdominal computer tomography angiography (CTA) and the 3D/Center Lumen Line reconstructions (3mensio Medical Imaging, Bilthoven, The Netherlands). Follow-up was conducted by duplex ultrasound (DUS)/ contrast enhancement DUS (CEUS) and/or CTA at 1, 6, and 12 months, and yearly thereafter. Early endpoints were technical (TS) and clinical success (CS), renal function worsening (≥30% of preoperative creatinine value) and type I/III endoleak. Mid-term endpoints were: type I/III endoleak, target visceral vessels patency, j-AAA shrinkage, freedom from reintervention and survival.
RESULTS: Twenty patients (94.7% of whom male; mean age: 73.4±5.9 years; ASA≥3: 100%) were enrolled. The mean neck length and j-AAA diameter were 2±1.4 mm (range: 0-4 mm) and 54.9±5 mm, respectively. Eleven (55%) endograft with two fenestrations and a scallop, 8 (45%) with three fenestrations and a scallop, and one (5%) with one fenestration and a scallop were implanted. Sixty-seven visceral vessels were re-vascularized. TS and CS were 100% and 95%, respectively (1/20 30-day mortality). Perioperative renal function worsening was observed in 15% of cases. The mean follow-up was 25±20 months (range: 2-72 months). No type I/III endoleak or occlusion of target visceral vessels occurred. There was j-AAA shrinkage in 65% of patients and no cases of j-AAA enlargement were observed. There were no FEVAR-related reinterventions. Survival at 12, 24, and 36 months were 89.4%, 80.5%, and 80.5%, respectively.
CONCLUSIONS: According to our results, the endovascular treatment for j-AAA, with α/β angle <60°, is safe and effective.


KEY WORDS: Abdominal aortic aneurysm - Vascular grafting - Stents - Endovascular procedures

inizio pagina